London, UK, May 15, 2019 – Dark Horse Consulting Group (DHC), the leading global consultancy practice specializing in cell and gene therapy product development, announced its participation in the Frost & Sullivan Executive Think Tank on Current challenges and future impact of cellular and genetic immunotherapies for human health to be held on May 15, 2019 in London, UK.
The event brings together a diverse group of thought leaders, from development and manufacturing organizations, academic institutions and public, non-profit bodies to consider progress and recent successes, along with facilitating insightful discussion of current and future manufacturing, regulatory and clinical challenges that face the field. DHC Principal Rob Allen, Ph.D. participated in this year’s event.
Various approaches to leveraging the human body’s own immune system to overcome tumor evasion are revolutionizing how cancer is treated. Cell and gene-based immunotherapies have the potential to generate long-term survival, with significant response rates and durable remissions occurring in both monotherapy and combination settings, in several different tumor types. Despite clinical trials successes, there are numerous challenges associated with the development, quality control, manufacturing and cost-effective use of cellular and genetic immunotherapies.
“The event was an very interesting and timely opportunity to look at recent successes achieved in the field of cellular immunotherapies for cancer, and focus on the challenges that need to be successfully addressed in order that novel therapies can be consistently manufactured at larger scale to enable treatments to reach larger groups of patients, who are in urgent need of these treatments,” said Rob Allen Ph.D., Principal at Dark Horse Consulting Group.
About Dark Horse Consulting Group
Dark Horse Consulting Group specializes in the development of cell and gene therapy products. All of our consultants have deep cell and gene therapy industry experience, spanning diverse functions including process development, device development, manufacturing, quality, regulatory, program management, business development, strategy, and financing/investor relations. Many of our consultants also bring experience from adjacent more mature sectors, including traditional biologics, small molecules, medical devices, and management consulting. As a result, we deeply understand the unique challenges faced by cell and gene Therapy developers and are able to apply best practices from other industries to address the needs of our clients.
About Frost & Sullivan
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success.